Article and Video CATEGORIES
We're heading into the season where much of the biggest news in the cancer world for the year is about to be released, in press releases and full presentations at our annual conference of the American Society for Clinical Oncology (ASCO). The meeting is June 1-5, in Chicago, and I'll be presenting some of my own work and chairing an educational session on the changing relationships between patients and doctors from the growing knowledge base of patients from online sources. There will be several other presentations that may well have implications that can change how we practice and offer new treatment options.
On June 28th, at 7 PM Eastern/4 PM Pacific, we're going to have two terrific guest faculty members leading us through the most interesting and important work: Dr. Joel Neal, Assistant Professor in Medical Oncology at Stanford, and Dr. Mark Socinski, Professor and Director of the Lung Cancer Program at the University of Pittsburgh. Rather than divide by cancer type, we'll see what the most relevant ASCO presentations are and then divide them between our two great speakers. Each will speak for about 30 minutes, followed by time for a question and answer session with our live audience.
Registration is free: all you need to do to join our ASCO Lung Cancer Highlight webinar is to sign up through this link. We'll be editing the content of the program to make it available in free podcasts, but you'll want to be there for the live event!
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…